News - Markets & Marketing, Dendreon

Filter

Popular Filters

US physicians to increase use of Zytiga in chemo-naive prostate cancer patients

27-06-2012

Physicians in the USA said they would use Zytiga (abiraterone acetate), from health care giant Johnson…

DendreonJanssenJohnson & JohnsonMarkets & MarketingNorth AmericaOncologyPharmaceuticalProvengeResearchZytiga

Zytiga overtaking Provenge in MCRPC

17-01-2012

Despite no current approval of Johnson & Johnson (NYSE: JNJ) subsidiary Janssen’s Zytiga (abiraterone)…

BiotechnologyDendreonJanssenJevtanaJohnson & JohnsonMarkets & MarketingNorth AmericaOncologyPharmaceuticalProvengeSanofiZytiga

Dendreon upbeat on Provenge sales

08-01-2012

US biotech firm Dendreon (Nasdaq: DNDN) pleased investors last week when it reported that revenue of…

BiotechnologyDendreonFinancialMarkets & MarketingOncologyProvenge

Cancer vaccines market set to see change, will grow to over $9 billion by 2018

24-10-2011

The global cancer vaccines market in seven key markets (the USA, France, Germany, Italy, Spain, UK and…

CervarixDendreonGardasilGlaxoSmithKlineGlobalMarkets & MarketingMerck & CoOncologyPharmaceuticalProvengeVaccines

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top